Logo

ENTX

Entera Bio Ltd.

ENTX

Entera Bio Ltd. • NASDAQ
$2.38 ▲ 0.00% (+0.00)
Market Cap $109.12 M
52w High $3.22
52w Low $1.50
Dividend Yield 0%
P/E -9.92
Volume 29.32K
Outstanding Shares 45.85M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.248M ▲ $-3.2M ▼ 0% $0.07 ▲ $-3.192M ▼
Q2-2025 $0 ▼ $2.668M ▲ $-2.656M ▼ 0% ▲ $-0.057 ▼ $-2.661M ▼
Q1-2025 $42K ▼ $2.563M ▲ $-2.567M ▼ -6.112K% ▼ $0.06 ▲ $-2.555M ▼
Q4-2024 $82K ▲ $2.337M ▼ $-2.358M ▲ -2.876K% ▲ $-0.063 ▼ $-2.326M ▲
Q3-2024 $42K $3.021M $-3.021M -7.193K% $0.08 $-3.01M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.574M ▼ $17.407M ▼ $2.173M ▼ $15.234M ▼
Q2-2025 $10.858M ▼ $19.667M ▼ $2.411M ▲ $17.256M ▼
Q1-2025 $12.573M ▲ $21.6M ▲ $2.221M ▲ $19.379M ▲
Q4-2024 $8.66M ▲ $9.39M ▲ $1.31M ▲ $8.08M ▲
Q3-2024 $6.915M $7.741M $1.289M $6.452M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.2M ▼ $-2.74M ▼ $-46.472K ▼ $803.742K ▲ $-2.271M ▼ $-2.787M ▼
Q2-2025 $-2.656M ▼ $-1.646M ▼ $-29.178K ▼ $13.058K ▼ $-1.7M ▼ $-1.675M ▼
Q1-2025 $-2.567M ▼ $-1.404M ▲ $-7.999K ▼ $13.337M ▲ $11.913M ▲ $-1.412M ▲
Q4-2024 $-2.358M ▲ $-1.467M ▲ $-3K ▼ $3.217M ▲ $1.747M ▲ $-1.47M ▲
Q3-2024 $-3.021M $-2.154M $0 $13K $-2.141M $-2.154M

Five-Year Company Overview

Income Statement

Income Statement Entera Bio is still a pure research-stage company with no product sales yet, so all activity flows through as research and operating expenses. Losses have been steady over the past several years rather than exploding, which suggests reasonably controlled spending for a biotech in development mode. Per‑share losses have been gradually shrinking, hinting at tighter cost management or some efficiency gains, but the business remains firmly pre‑revenue and dependent on future milestones or deals to change that picture.

Balance Sheet

Balance Sheet The balance sheet is very simple: a small pool of assets that is mostly cash, no debt, and equity that essentially mirrors the cash position. The lack of borrowing reduces financial risk but also highlights how dependent the company is on its existing cash and any future fundraising. The stated runway into the latter part of the decade suggests near‑term liquidity is planned for, but any delays or setbacks in trials could increase pressure to raise additional capital.

Cash Flow

Cash Flow Cash flows show a consistent, modest cash burn from operations, typical for a lean clinical‑stage biotech. There is essentially no spending on physical assets, reflecting a virtual or asset‑light model focused on trials and development rather than manufacturing or facilities. The core story is straightforward: cash is flowing out steadily to fund R&D, and future inflows will have to come from partnerships, licensing, or new capital until a product reaches the market.

Competitive Edge

Competitive Edge Entera Bio’s edge centers on its N‑Tab platform, which aims to turn injectable biologic drugs into oral tablets—an appealing shift for patients and prescribers if it works reliably. The company has built a meaningful patent estate and has an agreed regulatory path for its lead osteoporosis drug, which together create some protection and clarity. Collaborations with partners like OPKO help validate the platform and broaden its reach, but the company still faces intense competition from larger players and alternative oral biologic technologies, alongside the usual clinical and regulatory risks of drug development.

Innovation and R&D

Innovation and R&D Innovation is the heart of Entera Bio: the N‑Tab technology tackles the long‑standing challenge of getting fragile large molecules safely through the gut and into the bloodstream. The R&D pipeline is focused on oral versions of hormones and peptides for osteoporosis, hypoparathyroidism, short bowel syndrome, and obesity—areas where easier oral dosing could be highly attractive. Progress into late‑stage trials for EB613 and advancement of partnered programs will be key tests of whether the platform can consistently deliver real‑world benefits. Overall, R&D is focused, high‑risk, and potentially high‑reward, with many value inflection points still ahead.

Summary

Entera Bio is a small, focused, clinical‑stage biotech with no current revenue and a controlled but persistent cash burn supporting its research. The balance sheet is clean and simple, with cash but no debt, meaning execution risk is mainly scientific, regulatory, and financing‑related rather than tied to leverage. Its competitive story hinges on a differentiated oral delivery platform, protected by patents and supported by early clinical and partnership signals, but still unproven at commercial scale. The company’s future hinges on pivotal trial outcomes, successful partnerships, and continued access to capital, making it a classic early‑stage biotech profile: concentrated risk, concentrated dependence on a few key programs, and large potential upside if the technology platform is validated.

NEWS

November 18, 2025 · 8:00 AM UTC

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Read more

November 14, 2025 · 4:05 PM UTC

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

Read more

October 23, 2025 · 8:50 AM UTC

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Read more

October 16, 2025 · 8:45 AM UTC

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Read more